gilead sciences news - Search News

Morgan Stanley, Gilead

Morgan Stanley Upgrades Vir Biotechnology (VIR)

Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 141.11% Upside As of December 23,

Business Insider · 5h

Gilead upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for

YAHOO!Finance · 22m

Morgan Stanley upgrades Gilead on HIV treatment growth

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.

uk.investing.com on MSN · 1d

Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20

Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from "equal-weight," and have also increased their price target to $20 from $10. The analysts flagged

Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Zacks.com on MSN17h

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

FierceBiotech2d

Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors

This was the stock's fourth consecutive day of losses.

bovnews1d

BofA Securities Just Resumed Gilead Sciences Inc (GILD) Stock—What Does This Mean for Investors?

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

4don MSN

Here’s Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD)

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

Gilead Sciences Inc. stock outperforms competitors despite losses on the day

This was the stock's fifth consecutive day of losses.

BioPharma Dive1d

Galapagos, after research struggles, will split in two and revamp Gilead deal

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

ENDPOINTS NEWS19h

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

4don MSN

Gilead Sciences, Inc. (GILD): A Bull Case Theory

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

Gilead price target lowered to $83 from $84 at RBC Capital

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Morgan Stanley, Gilead

Related topics